BHC(SH:600721) Xin Lang Cai Jing·2025-10-28 01:35Core Insights - Baihua Pharmaceutical (600721.SH) reported a total operating revenue of 299 million yuan for Q3 2025, with a net profit attributable to shareholders of 32.67 million yuan [1] - The company's net cash inflow from operating activities was 12.36 million yuan, a decrease of 47.66 million yuan compared to the same period last year, representing a year-on-year decline of 79.40% [1] Financial Metrics - The latest debt-to-asset ratio stands at 29.16% [3] - The latest gross profit margin is 49.16%, a decrease of 0.24 percentage points from the previous quarter [3] - The latest return on equity (ROE) is 4.12% [3] - The diluted earnings per share (EPS) is 0.09 yuan [3] - The total asset turnover ratio is 0.27 times, and the inventory turnover ratio is 1.74 times [3] Shareholder Information - The number of shareholders is 33,200, with the top ten shareholders holding a total of 135 million shares, accounting for 35.05% of the total share capital [3] - The top ten shareholders and their respective holdings are as follows: - Mi Zaiqi: 8.99% - Mi Enhua: 6.70% - Yang Xiaoling: 4.95% - Xinjiang Xinnong Modern Investment Development Co., Ltd.: 4.36% - Li Jiancheng: 3.90% - Zhang Desheng: 2.12% - Ningbo Meishan Free Trade Port Area Daokang Xiangyun Investment Partnership (Limited Partnership): 1.28% - Shanghai Jiaqi Asset Management Center (Limited Partnership): 0.99% - China Securities Investor Protection Fund Co., Ltd.: 0.89% - Xinjiang Bingshe Material Management Co., Ltd.: 0.80% [3]